Abstract. Histone deacetylase inhibitors (HDACis) are anticancer molecules that epigenetically modulate cell functions. Chronic exposure of HCT116 colon cancer cells to SAHA has been investigated for a better understanding of resistance mechanisms but, surprisingly, a less aggressive tumor phenotype both in vitro and in vivo was obtained after exposure to increasing concentrations of SAHA. Indeed, HCT116/SAHA cells when injected into nude mice showed a reduced engraftment and growth with respect to HCT116 cells. This difference was not observed inoculating the cells into NOD/SCID mice that, differently from nude mice, lack NK activity, thus suggesting the involvement of the native immune response in impairment of HCT116/SAHA cell growth. In agreement with this result, a growing induction of NKG2D ligand expression, MICA and MICB, that are molecular mediators of NK cell killing, was confirmed in HCT116/SAHA chronically exposed to SAHA. A reduced clonogenic efficiency was also observed in HCT116/SAHA with respect to HCT116 cells. Interestingly, even after chronic exposure to SAHA, HCT116/SAHA cells developed only a moderate resistance to SAHA both in vitro and in vivo and they acquired a collateral sensitivity to anthracyclines. These results are of note and probably rely on the fact that, having simultaneously many different targets, HDACis would require many different mutations to display high resistance index. Moreover, to understand the molecular basis of HCT116/SAHA cell phenotype a gene expression profile of cancer genes was evaluated in HCT116 incubated with SAHA for 24 h and in HCT116/SAHA cells to identify selectively regulated genes.
Introduction
HDACis are a new class of anticancer agents. Many HDACis are currently in clinical trials as single agents and also in combination with classical chemotherapy or with biological therapies (1) . Zolinza ® (Vorinostat, Merck) and Istodax (Gloucester Pharmaceuticals) for the moment, are the only HDACis approved for the treatment of cutaneous T-cell lymphoma (2) .
HDACis represent a promising epigenetic treatment for cancer because in preclinical models they show pleiotropic antitumor effects in different tumor histotypes. In the literature many mechanisms of actions have been ascribed to HDACis likely depending on the cell type investigated (3, 4) . Understanding which mechanism is operating in a certain type of cell is at the basis for a more efficacious and less toxic therapy and should permit the treatment of many tumor histotypes (5) . Actually, the activity of HDACis in solid tumors and in major haematologic tumors is an important key point being addressed in many ongoing clinical trials (3) . HDAC enzymes play critical roles in many biological processes and each of them shows non-redundant functions (1, 3) .
HDACs can be divided into two families: the Zn-dependent family composed by class I (HDAC 1,2,3,8), class II (HDAC 4,5,6,7,9,10), class IV (HDAC 11) and the NADdependent SIR enzymes (1, 3) . The comprehension of which HDAC enzyme is important to be inhibited could lead to better pharmacological activities and also to progress in the cancer therapy using optimal combination and timing schedule. Nevertheless, currently HDACis both approved and in clinical development are mainly pan-inhibitors acting on Zn-dependent family (1, 3) .
Beside the demonstration of the potential activity in major tumor histotypes, important is to investigate whether HDACis can induce tumor resistance since in patients the drugs are administered daily for long periods.
Thus, HCT116 colon cancer cells were chronically exposed to SAHA. SAHA is an unselective, competitive HDACi that is inserted into the catalytic pocket of the natural substrate. In this study we provide evidence that the chronic inhibition of HDACs through the SAHA molecule induces a less aggressive phenotype of HCT116 colon cancer cells both in vitro and in vivo. Drug sensitivity assay. Different numbers of HCT116 cells or HCT116/SAHA cells were plated on 35-mm cell culture dishes. After 24 h SAHA or cytotoxic drugs were added. Cells exposed to SAHA were incubated for 7 days to allow colony formation, instead cells exposed to cytotoxic drugs, after 24 h of drug incubation, were washed and drug-free medium was added for 7 days. Each experiment was performed at least twice using triplicate samples. IC 50 concentrations were obtained plotting the clonogenic survival against drug concentrations.
Real-time PCR assays. Total RNA was prepared according to the procedure of the kit (Promega, CA, USA). cDNAs were synthesized using the 'Reverse Transcription System' kit (Promega) and amplified in the presence of 12.5 μl of 2X TaqMan Universal PCR Master Mix and 1.25 μl of 20X Taqman Gene Expression Assay (Applied Biosystems, CA, USA) to a final volume of 25 μl. The Taqman Gene Expression Assays were: Hs00741286_m1 for the MHC class I polypeptide-related sequence A (MICA), Hs00792952_m1 for the MHC class I polypeptide-related sequence B (MICB), Hs00360941_m1 for the UL16 binding protein 1 (ULBP1), Hs00225909_m1 for the UL16 binding protein 3 (ULBP3), Hs00373622_m1 for the retinoic acid early transcript 1E (RAET1E), Hs00606262_g1 for HDAC1, Hs00187320_m1 for HDAC 3, Hs00195814_m1 for HDAC 4, Hs00195869_m1 for HDAC 6, Hs00218503_m1 for HDAC 8.
As endogenous control, cDNA samples were amplified in the presence of the 20X Taqman Gene Expression Assay Hs99999904_m1 for the Cyclophilin A (PPIA). After 10 min of incubation at 95˚C for denaturation, samples were subjected to 45 cycles of PCR. Each cycle was 95˚C 15 sec and 60˚C 1 min. (7300 Real-Time PCR System, Applied Biosystems).
Tumor gene expression by real-time PCR array. cDNA samples were mixed with RT 2 qPCR Master Mix (SuperArray Bioscience Corp., MD, USA). The gene expression analysis was performed in a 96-well RT 2 Profiler PCR Array for human cancer (SuperArray Bioscience). In this array, each well contains a primer pair specific for one of 84 key genes representative of different pathways involved in human cancer, besides housekeeping genes and control wells. After an initial denaturation at 95˚C for 10 min, the cycling program was 95˚C, 15 sec and 60˚C, 1 min for 40 cycles. Raw data were analyzed with the ΔΔC t method. Data from control cells were set as calibrator for the relative quantification.
Tumor xenografts. Female athymic nude and NOD-SCID mice 6-7-weeks old (Charles River, Calco, Lecco, Italy) were used throughout the study. Mice were maintained in microisolator cages and supplied with sterile materials under standard conditions, according to UKCCCR guidelines (6) . Human tumor lines HCT116 and HCT116/SAHA originated from s.c. in vivo injection of tumor cells (15x10 6 cells/flank/0.2 ml). Tumor growth was followed by caliper measurement of length and width twice weekly. Tumor volume was calculated using the formula: volume (in mm 3 ) = width 2 x length/2 (7). Tumor-bearing mice were treated with SAHA at 50 mg/kg i.v. once daily, 5 days/week, for a total of 10 doses, starting when tumors were ~50 mm 3 in volume. SAHA was dissolved in DMSO and diluted before dosing with D5W (Dextrose 5%) to a final DMSO concentration not superior to 1% at a dose volume corresponding to 10 ml/kg body weight. The control group was treated with the vehicle.
Results
Chronic exposure to SAHA of HCT116 cells. Human colon cancer HCT116 cells are extremely sensitive to HDACis. In Table I Given the good sensitivity of this cell line, the cells were exposed to increasing concentrations of SAHA up to 6 μM for about 30 passages. The selection induced a different cell shape, as shown in Fig. 1 (HCT116/SAHA); indeed, cells grown in SAHA containing medium, were larger, more vacuolated and presenting pseudopodes. Moreover, HCT116/ Table I . Cytotoxic activity of HDAC inhibitors in HCT116 cells.
The cytotoxic activity was performed using Alamar blue assay. HCT116 cells were plated in 96-wells and after 24 h different HDACis concentrations were added for 96 h. 6 ) of HCT116 and HCT116/SAHA cell line were inoculated s.c. in 3 nude mice and the in vivo growth was observed ( Fig. 2A) . HCT116 tumor cells grew well and after 40 days from inoculum the tumor volume was around 1500 mm 3 . HCT116/SAHA tumor cells had a slow growing behavior and a reduced tumor take rate, indeed in 1 over 3 mice the tumor did not growth.
These differences in tumor take and tumor growth were instead not observed when HCT116 and HCT116/SAHA cells were xenografted in NOD/SCID mice (Fig. 2B) . This result correlates with the reduced tumorigenic activity in nude mice since it has been shown that mouse NK cells can induce lysis of human tumor cells (8) . Thus, although nude mice are immunodeficient hosts, it is possible that the residual immune system is an important component of the reduced in vivo growth of HCT116/SAHA cells.
HCT116/SAHA cells show a reduced cloning efficiency in vitro.
To investigate the proliferative ability of HCT116/ SAHA cells, the cloning efficiency was measured. Clonogenic data revealed that wild-type cell line was able to clone more efficiently than HCT116/SAHA cells (Table II) . In particular, HCT116 cells had a cloning efficiency of 19% while HCT116/SAHA cells had a cloning efficiency of 2% in the absence of any drugs. Moreover, the shape of the colonies was completely different from those formed by HCT116 cells (data not shown) in agreement with morphological data observed in Fig. 1 .
HCT116/SAHA cells maintain SAHA sensitivity in vitro and in vivo.
The sensitivity of HCT116/SAHA and HCT116 cells to SAHA was also measured (Table III) . In this experimental conditions a low level of resistance is displayed by HCT116/ SAHA cells. In particular, IC 50 was 0.54 and 2.7 μM for HCT116 and HCT116/SAHA, respectively. HCT116/SAHA cells were instead hypersensitive to two drugs belonging to the chemical class of anthracyclines (Table III) . HCT116/ SAHA cells are 5-and 4-fold more sensitive to doxorubicin and sabarubicin, respectively, than HCT116 cells. Fig. 4 shows the antitumoral activity of SAHA in HCT116 and HCT116/SAHA tumor xenografted in nude mice. The two tumor lines in the absence of any drug confirmed a completely different growth; instead the treated group reached after 2 week-treatment (day 20 post implant in the Figure) the same residual tumor volume. Important to be noted is the difference of growth of HCT116 and HCT116/SAHA tumors after the end of the treatment: indeed a fast and prompt re-growth of HCT116 tumor (full circle) was observed in contrast with a steady-state kinetics of tumor volume in HCT116/SAHA tumors (full triangle).
Gene expression profiling in HCT116/SAHA cells by realtime PCR array.
A real-time PCR array for the detection of 84 genes involved in cancer was performed to compare expression profiles of HCT116/SAHA, HCT116 and HCT116 cells exposed for 24 h to SAHA. Data were selected with a threshold of 3-fold-change in the expression (Fig. 5) .
As expected, the gene expression profile of HCT116/ SAHA cells was substantially different from that of HCT116 cells. In HCT116/SAHA cells, 15 out of 84 genes were up- Table III . Clonogenic survival of HCT116/SAHA cells and HCT116 cells exposed to anticancer drugs. 
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regulated respect to HCT116 gene expression (the proapoptotic factor BAD, the integrins ITGA1, ITGB1, ITGB3, the melanoma cell adhesion molecule MCAM, the transcriptional factor TWIST1, the putative metastasis suppressor MTSS1, the platelet-derived growth factor PDGFB, the regulatory subunit of (PI)-3 kinase PIKR31, the S100 calcium binding protein A4 S100A4, the inhibitor of urokinase plasminogen activator SERPINE1, the tyrosine kinase SYK, the anti-angiogenic factor thrombospondin THBS1, the interleukin 8 and the ependymin related protein EPDR1) while five genes were repressed (the transcription factors FOS and NFKB1, the synuclein-Á SNCG, the telomerase reverse transcriptase TERT and the vascular endothelial growth factor VEGF) in HCT116/SAHA cells.
We focused on genes that were selectively regulated in HCT116/SAHA cells with respect to HCT116 cells exposed for 24 h to the drug (Fig. 6) . In HCT116/SAHA cells 10 out of 84 genes were selectively regulated in HCT116/SAHA cells and some of them could at least in part justify the different behavior of HCT116/SAHA cells with respect to HCT116 cells.
Discussion
SAHA is a new anticancer agent belonging to the class of HDACis. After its approval by the US FDA in 2006 for the treatment of cutaneous T cell lymphoma, now SAHA is trying to find its value for the major hematological and solid tumors in more than 40 clinical trials looking for the right drug combinations. Up to now, the poor knowledge of HDAC functions have led to empirical clinical trials and empirical drug combinations. Thus, it is important to add information to direct effective clinical trials. With this aim, we selected HCT116 cells grown in the continuous presence of 6 μM SAHA. Drug resistance is the major obstacle of cancer chemotherapy since it leads to treatment failure and fatal consequences for patients. Even after the coming of target-therapy revolution, drug resistance is still a problem and strategies to overcome it are a challenge since the plasticity of cancer cells is due to mutations potentially allowing the survival in any kind of selective pressure; indeed frequently, both in vitro and in the clinical practice, combinations of drugs do not cure cancer because broad spectrum resistance is observed. This multidrug resistance is based on a vast array of mechanisms among which there are ABC transporters (9) . The HDACi depsipepide has been found to induce P-glycoprotein expression in T-cell lymphoma model and in normal and malignant PBMCs obtained from patients (10, 11) . These studies are of note since P-glycoprotein transports many agents among which doxorubicin and etoposide and indeed treatment with depsipeptide induced in acute promyelocytic leukemia cells (12) and in colon cancer cells a subsequent resistance to doxorubicin. Moreover, the resistance to depsipeptide is characterised by a very high resistance index (300-900-fold) as usually observed for cytotoxic agents. On the contrary, SAHA, a different chemical class among HDACis, kills both Pglycoprotein-positive and -negative cells (13) .
Both the study presented here and also results already published (14, 15) demonstrated that, even after prolonged exposure, SAHA can induce only a slight resistance index in HCT116 cells and a collateral sensitivity to anthracyclines. This result is of note and possibly rely on the fact that HDACis have simultaneously many targets, histones and other cellular proteins, and thus the induction of resistance would require many different mutations. Here, we show that HCT116/SAHA cells acquire a completely different shape, a reduced growth rate and that dramatically reduce their ability to form colonies. Moreover, HCT116/SAHA cells engraftment and growth as tumor xenograft in nude mice is reduced respect to HCT116 cells. This striking result might be at least in part due to the reduced growth rate observed in vitro but also to the ability of HDACis to modulate the expression of MHC class I chain related molecules, MICA and MICB, that binds to the activating immunoreceptor NKG2D. Indeed, it has been published that the induction of NKG2D ligand by treatment with HDACis renders leukemic and hepatoma cells more sensitive to NK cytolysis (16) (17) (18) (19) . The possible involvement of NK population in the reduced growth of HCT116/SAHA in vivo was also suggested by inoculating HCT116/SAHA cells into NOD SCID mice that, differently from nude mice, lack NK function. In this experimental system HCT116 and HCT116/SAHA cells have the same growth rate. Altogether these results show that the chronic exposure to SAHA renders cancer cells less tumorigenic both in vitro and in vivo and strikingly only slightly resistant to the selective agent SAHA.
Additionally, we also observed an interesting collateral sensitivity to anthracyclines whose targets are the enzymes DNA Topoisomerase II (Table III) . It is known that HDAC enzymes interact with DNA topoisomerase II (20, 21) and that the combination of HDAC inhibitors, added first, and DNA topoisomerase II poisons is synergistic both in vitro (22) (23) (24) (25) and in vivo (26) . These observations resulted in a phase I clinical trial using valproic acid followed by epirubicin in advanced solid tumors (27) in which responses were seen in heavily pre-treated patients as well as in patients thought to be epirubicin resistant.
Thus, the anthracycline sensitivity showed here suggests that also a chronic use of hydroxamic-based HDACi might induce/restore anthacycline sensitivity.
Finally, a low density PCR array was used to identify which genes, from different transformation and tumorigenesis pathways, were regulated in HCT116/SAHA cells. In particular, we tried to distinguish genes involved in the immediate response of cancer cells to SAHA from genes regulated only in cells exposed chronically to SAHA (Table IV) . Notably, a differential gene signature was found between HCT116 acutely exposed to SAHA and in HCT116 chronically exposed to SAHA. Some of the genes uniquely modulated in HCT116/SAHA cells might easily explain their reduced tumorigenicity. For example, the strong induction of the tumor suppressor gene SYK correlates with the observed phenotype in HCT116/SAHA cells. SYK is a tyrosine kinase localised in the centrosome that negatively affects mitotic progression (28, 29) , its expression is lost during disease progression (30, 31) and SYK reactivation suppressed invasion property of cancer cells (31) . Further studies are needed to define which of the genes are crucial in the definition of HCT116/SAHA cell phenotype.
In summary, cells selected in the presence of an epigenetic drug (SAHA), differently from the selection operated with a cytotoxic agent or targeted agents, are only slightly resistant to selection agent and acquire many unexpected features such as a reduced clonogenic and tumorigenic potential and collateral sensitivity to anthracyclines. Thus, it is possible to speculate that the induction of HDACi resistance in cancer cells, because of the pleitropic activity of HDACi, would require the many different mutations to occur. Table IV . Expression of genes differentially expressed in HCT116/SAHA cells with respect to HCT116 exposed for 24 h to SAHA by real-time PCR. 
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